Back to search
Gaucher Disease Type 3
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Gaucher Disease Type 3 trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Gaucher Disease Type 3 trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
This study is a Phase 3, non-randomized, multicenter, efficacy and safety study in adult patients with Gaucher disease Type 1, on stable treatment with enzyme r…
Recent studies have has shown that magnetic resonance spectroscopy (MRS) can provide validated neuronal markers in patients with Type 1 GD (GD1) who are on stab…
This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the dise…
For detailed information, please view our study website: https://pearltrial.ucsf.edu/ The investigators aims to determine the the maternal and fetal safety and…
The purpose of this research is to review data already collected and to collect new data from adults and children in England with Gaucher Disease to determine c…
In the first part of this study we found the highest dose of the vaccine that did not have too many side effects. We are now trying to find out what effects the…
A 96-week, open-label, Phase 2 study to evaluate the efficacy and safety of Nizubaglustat (AZ-3102) in patients with Gaucher disease type 3 (GD3).